LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)

S. Zhang,P. Zhao,X. Chen,X. Sun,J. Cui,Z. Chen,Q. Wang,Y. Bai,K. Gu,L. Wang,Z. Li,J. Wang,J. Zhou,H. Wang,G. Wang,Y. Zhou,J. Yao,L. Shen,S. Qin

doi:10.1016/j.annonc.2022.08.063

Abstract

Irinotecan liposome plus 5-FU/LV is one of the standard therapy for metastatic pancreatic cancer(mPC) with failed to gemcitabine-based therapy. HR070803 is a liposome formulation of irinotecan and this study aimed to investigate the efficacy and safety of HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV as the second-line treatment in patients with locally advanced pancreatic cancer(LAPC) or mPC who failed to gemcitabine-based therapy.

Full Text